BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20444752)

  • 1. Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants.
    Kim E; Choi CB; Kang C; Bae SC;
    Ann Rheum Dis; 2010 Oct; 69(10):1889-90. PubMed ID: 20444752
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
    Reynolds KK; Ramey-Hartung B; Jortani SA
    Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.
    Stamer UM; Stüber F; Muders T; Musshoff F
    Anesth Analg; 2008 Sep; 107(3):926-9. PubMed ID: 18713907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
    Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
    Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia.
    Zhang W; Yuan JJ; Kan QC; Zhang LR; Chang YZ; Wang ZY
    Minerva Anestesiol; 2011 Jan; 77(1):33-9. PubMed ID: 21150856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Side effects of tramadol: 12 years of experience in the Netherlands].
    Kabel JS; van Puijenbroek EP
    Ned Tijdschr Geneeskd; 2005 Apr; 149(14):754-7. PubMed ID: 15835626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
    Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
    Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
    Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH
    Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol.
    Orliaguet G; Hamza J; Couloigner V; Denoyelle F; Loriot MA; Broly F; Garabedian EN
    Pediatrics; 2015 Mar; 135(3):e753-5. PubMed ID: 25647677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype.
    Stamer UM; Stüber F
    Anaesthesia; 2007 Dec; 62(12):1294-5; author reply 1295-6. PubMed ID: 17991273
    [No Abstract]   [Full Text] [Related]  

  • 12. CYP2D6*2 Polymorphism as a Predictor of Failed Outpatient Tramadol Therapy in Postherpetic Neuralgia Patients.
    Nasare NV; Banerjee BD; Suryakantrao Deshmukh P; Mediratta PK; Saxena AK; Ahmed RS; Bhattacharya SN
    Am J Ther; 2016; 23(3):e697-707. PubMed ID: 23567787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.
    Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F
    Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice.
    Raffa RB; Stone DJ
    J Pharmacol Exp Ther; 2008 May; 325(2):500-6. PubMed ID: 18292293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
    Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
    J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of tramadol in children].
    Saudan S; Habre W
    Ann Fr Anesth Reanim; 2007 Jun; 26(6):560-3. PubMed ID: 17524604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the pharmacokinetics of tramadol: on the difference between CYP2D6 extensive and poor metabolizers.
    Di Patti F; Fanelli D; Pedersen RS; Giuliani C; Torricelli F
    J Theor Biol; 2008 Oct; 254(3):568-74. PubMed ID: 18640130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
    Halling J; Weihe P; Brosen K
    Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Side effects of opioid and gene variants].
    Sora I; Komatsu H; Igari M; Ide S; Ikeda K; Shimoyama N
    Masui; 2009 Sep; 58(9):1109-11. PubMed ID: 19764433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoalgesic effect of tramadol in relation to CYP2D6.
    Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH
    Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.